InMed appoints Eric A. Adams president, CEO, director
Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.
Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy.
Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany).
Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.
Chris Bogart will be stepping down as Interim CEO and resuming his role as SVP of Corporate Strategy and Investor Relations.
Additionally, InMed announces it has accepted the resignation of Paul Brennen as a Director of the Company.